News
PSTX
3.190
+3.57%
0.110
NCNO, OPI and MESO are among after hour movers
On the Move NCNO, OPI and MESO are among after hour movers. G-III Apparel Group and Bowman Consulting are among the losers. NCino, BMEA and BWMN were among the biggest gainers on the day.
Seeking Alpha · 2d ago
Poseida Therapeutics appoints Syed Rizvi as Chief Medical Officer
Poseida Therapeutics appoints Syed Rizvi as Chief Medical Officer, effective April 1, 2024. Most recently served as Chief medical officer of Caribou Biosciences. RizVI most recently worked for ETPoseida.
Seeking Alpha · 2d ago
Poseida Therapeutics Names Rizvi Chief Medical Officer
Poseida Therapeutics names Dr. Syed Rizvi as its next chief medical officer. The company says he has more than 20 years of experience in drug development. The appointment is effective April 1. Poseida is a clinical-stage cell and gene therapy company.
Dow Jones · 3d ago
Press Release: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024. Poseida is a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases. Dr. Rizvi is a seasoned executive with over 20 years of experience in drug development.
Dow Jones · 3d ago
Weekly Report: what happened at PSTX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at PSTX last week (0311-0315)?
Weekly Report · 03/18 09:07
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Poseida Therapeutics is expected to release results from the phase 1 study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma on April 8th of 2024. The company has the backing of Roche to advance its CAR-T program. The global multiple myleoma market size is projected to reach $31 billion by 2026.
Seeking Alpha · 03/17 04:40
Poseida spikes after FDA orphan status for CAR-T therapy
Healthcare Poseida spikes after FDA orphan status for CAR-T therapy. Shares of Poseida Therapeutics (NASDAQ:PSTX) traded higher on Wednesday. The FDA granted its orphan drug designation for a car-T cell therapy candidate developed by the company. The designation covers its use for multiple myeloma.
Seeking Alpha · 03/13 12:22
Poseida Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since March 2023 -- Data Talk
Poseida Therapeutics, Inc. ( PSTX ) is currently at $3.44, down $0.63 or 15.36% -- On pace for largest percent decrease since March 10, 2023. Currently down four of the past six days. Down 78.8% from its all-time closing high.
Dow Jones · 03/11 18:43
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Mesoblast shares jumped 13.4% to $2.4399 on Monday. The company announced FDA support of an accelerated approval pathway for end-stage heart failure patients. Kidpik Corp. Shares gained 238% in today's mid-day session.
Benzinga · 03/11 17:41
12 Health Care Stocks Moving In Monday's Intraday Session
Regencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) shares increased by 76.41% during the session. Mesoblast stock rose 22.79% and Graphite Bio stock moved upwards.
Benzinga · 03/11 17:31
ELTK, PSTX and LTRN among mid-day movers
Seeking Alpha · 03/11 16:49
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. Stocks were lower on Monday, with the Dow Jones index falling more than 150 points. Shares of EQT Corporation fell sharply after the company announced a merger agreement to acquire Equitrans Midstream. Ventyx Biosciences, Inc. Shares tumbled 18.5% to $8.09.
Benzinga · 03/11 14:37
Weekly Report: what happened at PSTX last week (0304-0308)?
Weekly Report · 03/11 09:07
3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts 
TipRanks · 03/11 06:32
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
TipRanks · 03/08 12:50
Buy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updates
TipRanks · 03/08 11:28
Poseida Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 11:20
HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Benzinga · 03/08 11:10
William Blair Sticks to Its Buy Rating for Poseida Therapeutics (PSTX)
TipRanks · 03/08 10:25
More
Webull provides a variety of real-time PSTX stock news. You can receive the latest news about Poseida Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PSTX
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.